

AMERICAN JOURNAL OF OPHTHALMOLOGY®

JULY 2003 • VOLUME 136

EDITORIAL

FESTSCHRIFT: A TRIBUTE TO THE ACCOMPLISHMENTS OF BRADLEY R. STRAATSMA, MD, JD
Spivey, Liesegang, Holland, Bartley

FESTSCHRIFT PERSPECTIVES

**THE EDITORIAL PROCESS FOR MEDICAL JOURNALS: I. AN INTRODUCTION OF A SERIES AND
DISCUSSION OF THE RESPONSIBILITIES OF EDITORS, AUTHORS, AND REVIEWERS**
Liesegang, Albert, Schachat, Minckler

OPHTHALMIC EDUCATION: WHERE HAVE WE COME FROM AND WHERE ARE WE GOING?
Liesegang, Hoskins, Albert, O'Day, Spivey, Sadun, Parke, Mondino

PERSPECTIVES ON DIABETIC RETINOPATHY
Aiello

GLAUCOMA CLINICAL TRIALS AND WHAT THEY MEAN FOR OUR PATIENTS
Lichter

CATARACT TREATMENT IN THE BEGINNING OF THE 21ST CENTURY
Olson, Mamalis, Werner, Apple

PERIPHERAL RETINAL DEGENERATIONS AND THE RISK OF RETINAL DETACHMENT
Lewis

CHANGING CONCEPTS IN THE MANAGEMENT OF CHOROIDAL MELANOMA
Robertson



AJO®

MONTHLY SINCE 1884
Full-text online at www.ajo.com

ELSEVIER
ISSN 0002-9394

AMERICAN JOURNAL OF OPHTHALMOLOGY®

ISSN 0002-9394 • VOL. 136, NO. 1 JULY 2003

CONTENTS

ORIGINAL ARTICLES

- **1 A comparison of anterior chamber and posterior chamber intraocular lenses after vitreous presentation during cataract surgery: The Department of Veterans Affairs Cooperative Cataract Study.** *Joseph F. Collins, ScD, Ronald N. Gaster, MD, FACS, William F. Krol, PhD, Cindy L. Colling, RPh, MS, Gail F. Kirk, MS, Thomas J. Smith, MD, and The VA Cooperative Cataract Study Group*

This large, multicenter study compared one year outcome results of patients receiving either anterior chamber or posterior chamber intraocular lens implants after vitreous presentation during cataract surgery. Patients receiving posterior chamber lenses had better visual acuity at one year.

- **10 Incidence and progression of cataract in the Melbourne Visual Impairment Project.** *Catherine Anne McCarty, PhD, MPH, Bickol Nanjan Mukesh, PhD, Peter N. Dimitrov, BOrthop, and Hugh Ringland Taylor, MD, FRACO*

The purpose of this study was to quantify the 5-year incidence of cataract and cataract surgery in the Melbourne Visual Impairment Project cohort. The authors found that the cataract incidence data confirmed the need to plan both primary prevention programs and adequate surgical services to meet the anticipated increase in cataract screening procedures with an aging population.

- **18 Medical therapy cost considerations for glaucoma.** *Richard G. Fiscella, RPh, MPH, Amy Green, PharmD, Daniel H. Patuszynski, and Jacob Wilensky, MD*

The authors sought to determine the calculated daily patient cost (cost minimization) of medical glaucoma therapy and to review cost trends. They found that newer glaucoma medications exhibit similar costs per day com-

pared to many traditional medications, especially with greater price increases in older brand-only products since 1999.

- **26 Detection of glaucomatous visual field changes using the Moorfields regression analysis of the Heidelberg Retina Tomograph.** *Stefano Miglior, MD, Magda Guareschi, MD, Elena Albé, MD, Silvia Gomasasca, MD, Mauro Vavassori, and Nicola Orzalesi, MD*

In a paired comparison performed on the same population, the Moorfields regression analysis of the Heidelberg Retinal Tomograph revealed a higher diagnostic accuracy than multivariate discriminant analysis in the detection of glaucomatous visual field defects.

- **34 Multifocal visual evoked potential responses in glaucoma patients with unilateral hemifield defects.** *Pharmornsak Thienprasiddhi, MD, Vivienne C. Greenstein, PhD, Candice S. Chen, MD, Jeffrey M. Liebmann, MD, Robert Ritch, MD, and Donald C. Hood, PhD*

The multifocal visual evoked potential (mfVEP) technique can detect glaucomatous visual field defects. In this study of glaucomatous eyes with visual field defects limited to one hemifield, the mfVEP can detect damage in the unaffected hemifield.

- **41 Plasma homocysteine is elevated in patients with exfoliation syndrome.** *Roberto M. Vessani, MD, Robert Ritch, MD, Jeffrey M. Liebmann, MD, and Mark Jofe, MD*
- Plasma homocysteine levels are elevated in patients with exfoliation syndrome with and without glaucoma compared to controls with no ocular disease and to patients with normal-tension glaucoma.

AJO®